公开(公告)号：US20180170999A1

公开(公告)日：2018-06-21

申请号：US15737259

申请日：2016-06-29

申请人： Sanford-Burnham Medical Research Institute ,  PFIZER INC.

发明人： Carl F. Ware ,  John Sedy ,  Tigran Aivazian ,  Brian Miller ,  Natasha K. Crellin

IPC分类号： C07K14/71 ,  A61K38/17 ,  A61K45/06 ,  C07K14/705

CPC分类号： C07K14/71 ,  A61K38/00 ,  A61K38/17 ,  A61K45/06 ,  C07K14/70578 ,  C07K2319/30

摘要： The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.

公开(公告)号：US11939367B2

公开(公告)日：2024-03-26

申请号：US17188912

申请日：2021-03-01

申请人： Sanford Burnham Prebys Medical Discovery Institute ,  PFIZER INC.

发明人： Carl F. Ware ,  John Sedy ,  Tigran Aivazian ,  Brian Miller ,  Natasha K. Crellin

IPC分类号： C07K14/705 ,  A61K38/17 ,  A61K45/06 ,  A61K47/68 ,  C07K14/71 ,  C07K14/715 ,  C07K19/00 ,  A61K38/00

CPC分类号： C07K14/71 ,  A61K38/17 ,  A61K38/177 ,  A61K38/1793 ,  A61K45/06 ,  A61K47/68 ,  C07K14/70578 ,  C07K14/70596 ,  C07K14/715 ,  C07K19/00 ,  A61K38/00 ,  C07K2319/30

摘要： The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.

公开(公告)号：US20240247047A1

公开(公告)日：2024-07-25

申请号：US18442988

申请日：2024-02-15

申请人： Sanford Burnham Prebys Medical Discovery Institute ,  PFIZER INC.

发明人： Carl F. Ware ,  John Sedy ,  Tigran Aivazian ,  Brian Miller ,  Natasha K. Crellin

IPC分类号： C07K14/71 ,  A61K38/00 ,  A61K38/17 ,  A61K45/06 ,  A61K47/68 ,  C07K14/705 ,  C07K14/715 ,  C07K19/00

CPC分类号： C07K14/71 ,  A61K38/17 ,  A61K38/177 ,  A61K38/1793 ,  A61K45/06 ,  A61K47/68 ,  C07K14/70578 ,  C07K14/70596 ,  C07K14/715 ,  C07K19/00 ,  A61K38/00 ,  C07K2319/30

摘要： The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.

公开(公告)号：US10961297B2

公开(公告)日：2021-03-30

申请号：US15737259

申请日：2016-06-29

申请人： Sanford Burnham Prebys Medical Discovery Institute ,  Pfizer Inc.

发明人： Carl F. Ware ,  John Sedy ,  Tigran Aivazian ,  Brian Miller ,  Natasha K. Crellin

IPC分类号： A61K38/17 ,  C07K14/715 ,  C07K14/71 ,  A61K45/06 ,  C07K14/705 ,  A61K38/00

摘要： The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.